Recipharm reports record 2024 revenue and strategic milestones

• Record-breaking 2024 revenue: €827 million (+7% YoY), driven by strong growth and strategic execution
• Biologics growth: record contract signings and advancements in continuous manufacturing
• Increased pre-filled syringes (PFS) and lyo capacity: expanded production ensures immediate availability
• Enhanced product development: significant investments in OSD and SFF capabilities.

Recipharm, a leading global contract development and manufacturing organisation (CDMO), achieved a record-breaking €827 million in revenue for 2024, marking a 7% year-over-year increase. This success reflects Recipharm’s continued focus on strategic execution, customer-centric innovation and operational excellence across its global operations.

Greg Behar, CEO of Recipharm, commented: “2024 was a year of exceptional transformation and achievement for Recipharm. Our record-breaking revenue and strategic advancements reaffirm our commitment to being a trusted partner to the pharmaceutical and biotech industries. By focusing on customer collaboration, innovation and operational excellence, we have strengthened our position for even greater success in 2025. Recent investments and partnerships have significantly expanded our capacity in key areas such as pre-filled syringes (PFS) and lyophilisation, ensuring we can meet the evolving needs of our customers with agility and expertise.”

2024: a year of successful transformation and strategic growth
Following the carve-out of its inhaled and nasal drug-device business into Bespak and other transformational initiatives, Recipharm optimised its global operations to meet evolving market needs. In doing so, the company successfully reinforced its core focus on Oral Solid Dosage (OSD), Sterile Fill & Finish (SFF) and ReciBioPharm, its biologics and ATMPs division. These strategic efforts further strengthened Recipharm’s position as a trusted partner for both leading pharmaceutical companies and emerging biotechs.

Key achievements include:

• Biologics success: ReciBioPharm secured over 140 contracts spanning several new biological modalities, including nucleic acid-based RNA and plasmid DNA production, live viruses and viral vectors as well as live-microbial biopharmaceutical products. Notably, it recently received a significant three-year grant from the Gates Foundation to advance xRNA production technologies and improve access to RNA vaccines in Low- and Middle-Income Countries (LMICs).
• Biologics expansion: ReciBioPharm expanded its service portfolio to include sgRNA manufacturing, through a strategic partnership with Hongene. This collaboration streamlines the development and manufacturing process for RNA-based therapeutics, reducing logistical complexities associated with multiple CDMOs and ultimately accelerating drug development.
• Global manufacturing expansion: Recipharm increased pre-filled syringes (PFS) and lyophilisation capacity across Europe and the US, ensuring immediate availability. Its Wasserburg, Germany site now offers over 60 million PFS and vial capacity, while it also added over 100 million ready-to-use sterile units in the US.
• Customer-driven innovation: Recipharm introduced ReciPredict, a predictive tool designed to optimise drug development and manufacturing timelines. By leveraging advanced analytics and simulation, ReciPredict enhances efficiency, reduces delays and accelerates time-to-market for pharmaceutical products.
• Enhanced product development capabilities: Recipharm strengthened its expertise in OSD and SFF product development, establishing a new lab for sterile liquids and lyophilised products. The company also introduced GMP pilot-scale lines for BFS, PFS, and vials. Additionally, Recipharm advanced its high-potency capabilities, with oncologic oral products gearing up for commercial launch, further reinforcing its ability to support customers from early-stage product development to commercialisation.
• Strengthened BFS leadership: Recipharm further solidified its leadership in Blow-Fill-Seal (BFS) technology, responding to the increasing demand for single-unit sterile dose solutions, including vaccines, with strong market activity.
• Regulatory excellence: Recipharm secured multiple FDA and global regulatory approvals, further strengthening its reputation for quality and compliance. The implementation of a new centralised digital quality management system enhanced operational efficiency and streamlined compliance processes.
• Leading in sustainability: Recipharm remains on course to achieve its validated SBTi targets, reducing Scope 1 greenhouse gas emissions by 15% and Scope 2 by 48% (2021–2024), with a goal of net-zero Scope 2 by 2030. In addition, it achieved 100% renewable electricity across all sites.

Looking ahead to 2025
Recipharm enters 2025 with strong momentum, focusing on expanding continuous manufacturing, high-potency product development and manufacturing, and further investments in SFF. By leveraging cutting-edge technologies and strategic collaborations, Recipharm continues to provide world-class expertise from development to commercialisation.

Recipharm remains committed to driving industry-leading solutions that support the evolving needs of pharmaceutical and biotech partners worldwide.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com

Media contact:
Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708